Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-22T16:13:32.878Z Has data issue: false hasContentIssue false
  • English
  • Français

Management of sarcomatoid salivary duct carcinoma of the submandibular gland duct with coexisting seropositive human immunodeficiency virus

Published online by Cambridge University Press:  24 April 2013

W F Mourad ,
K S Hu ,
R A Shourbaji  and
L B Harrison
W F Mourad*
Affiliation:
Department of Radiation Oncology, Beth Israel Medical Center, New York, NY, USA Department of Radiation Oncology, Albert Einstein College of Medicine, New York, NY, USA
K S Hu
Affiliation:
Department of Radiation Oncology, Beth Israel Medical Center, New York, NY, USA
R A Shourbaji
Affiliation:
Department of Radiation Oncology, Beth Israel Medical Center, New York, NY, USA
L B Harrison
Affiliation:
Department of Radiation Oncology, Beth Israel Medical Center, New York, NY, USA
*
Address for correspondence: Dr W F Mourad, 10 Union Square East, Suite 4G, New York, NY 10003, USA Fax: +01 212 844 8086 E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

Sarcomatoid salivary duct carcinoma of the submandibular gland is extremely rare. This paper highlights the impact of surgery and adjuvant radiation therapy on the outcome of this disease.

Methods:

A 59-year-old man with human immunodeficiency virus presented with a painless, rapidly growing left neck mass. Biopsy followed by surgical excision of the left submandibular gland revealed sarcomatoid salivary duct carcinoma of the submandibular gland duct with perineural invasion and close margins, for which he underwent adjuvant radiotherapy. Post-operative positron emission tomography and computed tomography revealed no residual or metastatic disease. Pathological analysis of tumour–node–metastasis staging revealed a T2 N0 M0 (stage II) tumour.

Results:

The patient tolerated his treatment without serious acute or long-term side effects. There was no evidence of disease on comprehensive examination or on positron emission tomography or computed tomography scans at the 4.6-year follow up.

Conclusion:

Surgery followed by adjuvant radiotherapy provided practical locoregional control with acceptable toxicity. Further detailed case reports are warranted to optimise the management of this rare malignancy.

Keywords

Submandibular GlandSalivary DuctsCarcinomaPathologyHuman Immunodeficiency VirusRadiotherapy
Type
Clinical Records
Information
The Journal of Laryngology & Otology , Volume 127 , Issue 6 , June 2013 , pp. 621 - 624
Copyright
Copyright © JLO (1984) Limited 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Steiner, M, Gould, AR, Miller, RL, Johnson, JA. Malignant tumors of Stensen's duct. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999;87:73–7CrossRefGoogle ScholarPubMed
2Wharton, T. Adenographia Sive Glandularum Totius Corporis Description. London: Wharton, 1656;128–37Google Scholar
3Henley, JD, Seo, IS, Dayan, D. Sarcomatoid salivary duct carcinoma of the parotid gland. Hum Pathol 2000;31:208–13CrossRefGoogle ScholarPubMed
4Mori, M, Ohta, M, Maegawa, H, Hara, T, Imamura, Y. Sarcomatoid salivary duct carcinoma of the submandibular gland: a case report. Acta Cytol 2010;54:695–700CrossRefGoogle ScholarPubMed
5Nagao, T, Gaffey, TA, Serizawa, H, Iwaya, K, Watanabe, A, Yoshida, T et al. Sarcomatoid variant of salivary duct carcinoma clinicopathologic and immunohistochemical study of eight cases with review of the literature. Am J Clin Pathol 2004;122:222–31CrossRefGoogle ScholarPubMed
6Padberg, BC, Sasse, B, Huber, A, Pfaltz, M. Sarcomatoid salivary duct carcinoma. Ann Diagn Pathol 2005;9:86–92CrossRefGoogle ScholarPubMed